Dalrada Technology Group, Inc. (DHTI): debt financing — Dalrada Tech Group amends 8-K: subsidiary Genefic secures up to $25M financing; CEO personal guaranty

Dalrada Technology Group, Inc.

Corrected total commitment from $20M to $25M: $20M SBLC agreement + $5M ARL receivables facility.
CEO Brian Bonar provides unlimited personal guaranty; parent company pledges substantially all assets.
Availability period through Dec 31, 2030; fees include $140k cash, $165k note, $225k warrant for 5% equity.
Financing supports Genefic's healthcare specialty pharmacy operations.

item 2.03 item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Dalrada Technology Group, Inc. incurred revolving credit of $5,000,000 with IBS Private Credit Fund IV, LLC.

Instrument: revolving credit
Principal: $5,000,000
Counterparty: IBS Private Credit Fund IV, LLC
Event: incurrence

Exact text from the filing

(ii) the related ARL Agreement dated the same day, under which IBS Private Credit Fund IV, LLC (or its affiliate) may extend revolving credit through the purchase of accounts receivable up to $5,000,000

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Dalrada Technology Group, Inc. entered into Master Performance Standby Letter of Credit and Guaranty Agreement with IBS Equity Fund III, LLC, a division of IBS Investment Bank valued at $20,000,000 (effective 2025-12-31).

Action: entry
Agreement: credit facility
Counterparty: IBS Equity Fund III, LLC, a division of IBS Investment Bank
Value: $20,000,000
Effective: 2025-12-31

Exact text from the filing

On January 21, 2026, Genefic Inc. ("Genefic"), a wholly-owned subsidiary of Dalrada Technology Group, Inc. (the "Company"), entered into a Master Performance Standby Letter of Credit and Guaranty Agreement dated December 31, 2025 (the "SBLC Agreement") with IBS Equity Fund III, LLC, a division of IBS Investment Bank (the "Secured Party").

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Dalrada Technology Group, Inc. entered into Credit, Security, and Account Purchase Agreement with IBS Equity Fund III, LLC (or its affiliate, IBS Private Credit Fund IV, LLC) valued at $5,000,000 (effective 2025-12-31).

Action: entry
Agreement: credit facility
Counterparty: IBS Equity Fund III, LLC (or its affiliate, IBS Private Credit Fund IV, LLC)
Value: $5,000,000
Effective: 2025-12-31

Exact text from the filing

The SBLC Agreement supports a related Credit, Security, and Account Purchase Agreement (the "ARL Agreement") dated the same day, under which the Secured Party (or its affiliate, IBS Private Credit Fund IV, LLC) may extend revolving credit through the purchase of accounts receivable on behalf of Genefic for the benefit of third-party beneficiaries in connection with Genefic's business operations, up to $5,000,000.

View on SEC.gov

71 debt financings filed in the last 30 days. Browse all debt financings →

Dalrada Technology Group, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-26-000673

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.